Latest Conference Articles

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

SDPA President Laura Bush DMSc, PA-C, DFAAPA, shares exciting news about the name change as the Summer Conference begins to wind down.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

The inaugural RAVE conference begins today in Chicago, Illinois.

Renata Block, MMS, PA-C, discusses contracts, work environments, and more with SDPA presenter and past president Gina Mangin, MPAS, PA-C.

Jennifer Hsiao, MD, shares insights on emerging therapies and comprehensive care strategies at the 2024 SDPA Annual Summer Dermatology Conference.

What's the preferred sunscreen and why? Renata Block, MMS, PA-C, talks to the attendees of the 2024 SDPA Annual Summer Dermatology Conference.

The SDPA President Elect shared insights, hopes for the field, and the importance of leadership.

This special literature review yields a deeper understanding of issues like treating acne, nutraceuticals, and more.

Laura Bush, DMSc, PA-C, DFAAPA, talks to Renata Block, MMS, PA-C, about her SDPA presidency, the future, and the importance of a positive outlook.

Poster presented at the SDPA conference reported Effisayil 2 data indicating spesolimab improved Dermatology Life Quality Index scores in patients with generalized pustular psoriasis.

Renata Block, MMS, PA-C, and Faseeha Raza, PA-C, discuss the DPAF, philanthropy, leadership, and the importance of patient care.